Health

Mounjaro and Zepbound Shortages Are Over, FDA Says

The U.S. Food and Drug Administration (FDA) has declared an end to shortages of the GLP-1 drugs Mounjaro and Zepbound, a move that means online pharmacies will have to stop selling compounded versions of these medicines.

Tirzepatide, the active ingredient in both Mounjaro for type 2 diabetes and Zepbound for weight loss, was in short supply for more than two years. But the drugmaker Eli Lilly is “currently meeting or exceeding demand” for all doses of these medicines and should continue to do so going forward, the FDA said in a December 19 statement.

The End of Compounded Tirzepatide?

With supply issues resolved, so-called compounding pharmacies that have been legally selling copycat versions of these medicines during the shortage will have to stop doing so within the next two to three months, the FDA said.

While some patients with insurance coverage for Mounjaro and Zepbound may now find it easier to get prescriptions filled at their regular pharmacies, people who have been paying out-of-pocket for copycat versions may now have a harder time accessing or affording treatment, says Melanie Jay, MD, a professor and a codirector of the obesity research program at the New York University Grossman School of Medicine in New York City.


Source link

Related Articles

Back to top button